OncoFusion Therapeutics: OncoFusion Therapeutics Reacquires Rights to BET Bromodomain Inhibitors
OncoFusion Therapeutics Inc. announced today that it has reached an agreement with Medivation Inc. to reacquire the rights to certain compounds targeting Bromodomain and ExtraTerminal BET proteins identified and developed under a re...
Read full article »
Co-Founder
Shaomeng Wang
OncoFusion focuses on the discovery and development of gene fusion technology for the treatment of cancer.
Read more